Document Detail

Brentuximab vedotin.
MedLine Citation:
PMID:  23155186     Owner:  NLM     Status:  Publisher    
Brentuximab vedotin (SGN-35), an intravenously administered CD30-specific antibody-drug conjugate, has recently been approved by the U.S. Food and Drug Administration for two indications, including (1) patients with Hodgkin's lymphoma (HL) relapsing after autologous stem cell transplantation (ASCT), or after two multi-drug regimens in HL patients who are not candidates for ASCT; and (2) patients with systemic anaplastic large cell lymphoma (ALCL) who failed at least one prior multi-drug chemotherapy regimen. HL and ALCL patients treated with brentuximab vedotin demonstrated markedly high response rates for a single agent, exceeding 70% and 80% for HL and ALCL, respectively. The complete response rate was equally as impressive, at 34% and 57% for HL and ALCL, respectively. These and results from many upcoming clinical trials, where brentuximab vedotin is being investigated in the frontline setting, promise to profoundly change how we manage the CD30 positive lymphoproliferative malignancies. The mechanism of action, preclinical antitumor activity, and clinical activity of brentuximab vedotin against HL, ALCL, and other CD30 expressing lymphoma are reviewed.
Changchun Deng; Beiqing Pan; Owen A O'Connor
Related Documents :
1695306 - Timing of blood pressure measurements in determining anomalies in duration of effect of...
3800116 - Pharmacokinetics and endometrial tissue concentrations of ticarcillin given to the hors...
24785576 - Preparation and evaluation of orally disintegrating tablets of taste masked phencynonat...
24262116 - Adverse childhood experiences and gender influence treatment seeking behaviors in obses...
20873946 - Emerging oral agents for multiple sclerosis.
750966 - Are there two classes of classically-conditioned responses?
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-11-15
Journal Detail:
Title:  Clinical cancer research : an official journal of the American Association for Cancer Research     Volume:  -     ISSN:  1078-0432     ISO Abbreviation:  Clin. Cancer Res.     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-16     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9502500     Medline TA:  Clin Cancer Res     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Medicine, Columbia Univeristy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Targeted delivery of paclitaxel to EphA2-expressing cancer cells.
Next Document:  Inside the black box: starting to uncover the underlying decision rules used in a one-by-one expert ...